Ingalls & Snyder LLC Has $996,000 Holdings in ImmunoPrecise Antibodies Ltd. (NASDAQ:IPA)

Ingalls & Snyder LLC grew its position in shares of ImmunoPrecise Antibodies Ltd. (NASDAQ:IPA) by 20.3% during the 3rd quarter, Holdings Channel.com reports. The institutional investor owned 1,558,892 shares of the company’s stock after buying an additional 263,451 shares during the quarter. Ingalls & Snyder LLC owned 0.05% of ImmunoPrecise Antibodies worth $996,000 at the end of the most recent reporting period.

Separately, Renaissance Technologies LLC grew its holdings in ImmunoPrecise Antibodies by 70.0% during the 2nd quarter. Renaissance Technologies LLC now owns 63,910 shares of the company’s stock worth $65,000 after acquiring an additional 26,310 shares during the period. Hedge funds and other institutional investors own 6.70% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently commented on IPA shares. Benchmark dropped their price target on ImmunoPrecise Antibodies from $5.00 to $3.00 and set a “speculative buy” rating on the stock in a research report on Wednesday, August 14th. HC Wainwright reiterated a “buy” rating and set a $9.00 target price on shares of ImmunoPrecise Antibodies in a report on Tuesday, September 17th.

ImmunoPrecise Antibodies Trading Down 4.0 %

Shares of IPA stock opened at $0.36 on Wednesday. The company has a market cap of $10.41 million, a PE ratio of -0.46 and a beta of 0.06. The company has a debt-to-equity ratio of 0.36, a quick ratio of 0.82 and a current ratio of 0.99. ImmunoPrecise Antibodies Ltd. has a fifty-two week low of $0.32 and a fifty-two week high of $2.60. The stock’s fifty day moving average price is $0.51 and its two-hundred day moving average price is $0.76.

ImmunoPrecise Antibodies (NASDAQ:IPA) last released its quarterly earnings results on Monday, September 16th. The company reported ($0.11) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.09) by ($0.02). ImmunoPrecise Antibodies had a negative return on equity of 65.37% and a negative net margin of 114.67%. The firm had revenue of $3.85 million for the quarter, compared to the consensus estimate of $4.96 million. Equities analysts predict that ImmunoPrecise Antibodies Ltd. will post -0.3 EPS for the current fiscal year.

ImmunoPrecise Antibodies Profile

ImmunoPrecise Antibodies Ltd., together with its subsidiaries, operates as a biotherapeutic research and technology company in Canada and internationally. It provides NonaVac DNA for complex protein classes, including GPCRs and ion channels; and Rapid Prime, a positive monoclonal antibodies for generating anti-idiotypic antibodies, and producing monoclonal antibodies against conformational epitopes.